INDIANAPOLIS (AP) — Eli Lilly and Co.'s third-quarter earnings jumped 38 percent as the drugmaker cut costs while international sales climbed, but total revenue lagged and looming patent expirations remain a concern.
The Indianapolis company raised its expectations for net income for the entire year, and said Thursday it earned $1.3 billion, or $1.18 per share, in the three months that ended Sept. 30.
That's up from the $941.8 million, or 86 cents per share, in the same period last year, when Lilly recorded nearly $550 million in one-time charges tied to litigation and the sale of a manufacturing site.
Revenue for the past three months rose 2 percent to $5.65 billion, …
No comments:
Post a Comment